NASDAQ:HILS Hillstream BioPharma (HILS) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free HILS Stock Alerts $0.37 +0.01 (+2.78%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.3750-Day Range$0.23▼$0.4752-Week Range$0.19▼$2.65Volume62,089 shsAverage Volume1.39 million shsMarket Capitalization$6.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Hillstream BioPharma alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Hillstream BioPharma Stock (NASDAQ:HILS)Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Read More HILS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HILS Stock News HeadlinesApril 17, 2024 | morningstar.comHill & Smith PLC HILSOctober 31, 2023 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.September 22, 2023 | finance.yahoo.comHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 21, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 11, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 8, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 30, 2023 | benzinga.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.August 25, 2023 | seekingalpha.comNMTRQ 9 Meters Biopharma, Inc.August 9, 2023 | finance.yahoo.comHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023July 20, 2023 | finance.yahoo.comHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215July 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsJuly 6, 2023 | finance.yahoo.comHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersJune 9, 2023 | finance.yahoo.comHILS - Hillstream BioPharma, Inc.May 15, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 4, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesApril 29, 2023 | benzinga.comHillstream BioPharma Stock (NASDAQ:HILS), Short Interest ReportApril 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public OfferingApril 28, 2023 | marketwatch.comHillstream BioPharma Shares Slide Premarket on Stock Offering >HILSApril 28, 2023 | investorplace.comWhy Is Hillstream BioPharma (HILS) Stock Down 57% Today?April 28, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Pricing of Public OfferingApril 27, 2023 | finance.yahoo.comHillstream BioPharma Announces Proposed Public OfferingApril 13, 2023 | tmcnet.comHillstream BioPharma Selects OncoBay Clinical to Advance ClinicalSee More Headlines Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HILS CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-188.44% Return on Assets-149.61% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book0.77Miscellaneous Outstanding Shares17,603,000Free Float12,280,000Market Cap$6.50 million OptionableNot Optionable Beta3.08 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Randy D. Milby MBA (Age 69)Pres, Chairman & CEO Comp: $471.94kMr. Sireesh Appajosyula Pharm.D. (Age 47)COO & Director Comp: $64.96kMr. Thomas P. Hess CPA (Age 59)MBA, Chief Financial Officer Key CompetitorsEnsysce BiosciencesNASDAQ:ENSCSoligenixNASDAQ:SNGXArtelo BiosciencesNASDAQ:ARTLZyVersa TherapeuticsNASDAQ:ZVSAEvoke PharmaNASDAQ:EVOKView All Competitors HILS Stock Analysis - Frequently Asked Questions Should I buy or sell Hillstream BioPharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HILS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HILS, but not buy additional shares or sell existing shares. View HILS analyst ratings or view top-rated stocks. How have HILS shares performed in 2024? Hillstream BioPharma's stock was trading at $0.2305 on January 1st, 2024. Since then, HILS stock has increased by 60.1% and is now trading at $0.3691. View the best growth stocks for 2024 here. When did Hillstream BioPharma IPO? Hillstream BioPharma (HILS) raised $21 million in an IPO on Wednesday, January 12th 2022. The company issued 3,750,000 shares at $5.00-$6.00 per share. How do I buy shares of Hillstream BioPharma? Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HILS) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
